What does the evidence say about Glucosamine Joint Pain Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Glucosamine Joint Pain Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - Non-steroidal anti-inflammatory drugs (NSAIDs), as first-line pharmacological agents, provide symptomatic improvement but are associated with gastrointestinal bleeding and cardiovascular risks upon prolonged administration. [Shi Chuankai (2026); evidence level 1] - Systematic reviews and meta-analyses of observational studies indicate substantial heterogeneity in NSAID utilization among OA patients, with generally limited evidence quality (). [Shi Chuankai (2026); evidence level 1] - Emerging evidence has identified histone lactylation—a lactate-driven epigenetic modification—as a key player in OA progression, suggesting that targeting lactate metabolism or lactylation pathways may offer new therapeutic opportunities (). [Shi Chuankai (2026); evidence level 1] - 1 2 4 5 6 7 Osteoarthritis (OA) represents a leading global cause of joint pain and functional disability, substantially impairing patients’ quality of life (). [Shi Chuankai (2026); evidence level 1] - To ensure a robust synthesis of evidence, we conducted a systematic search of PubMed, Embase, and Web of Science (2020-2025) for high-quality clinical trials, meta-analyses, and guidelines. [Wang H (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.